e-Therapeutics plc ('e-Therapeutics' or 'the Company') Notification of Full Year Results Date Oxford and Newcastle, UK - 10 March 2015 - e-Therapeutics plc (AIM: ETX), the drug discovery and development company, will announce its full year results for the period ended

31 January 2015 on Tuesday, 31 March 2015.
A group analyst briefing will be held at 11:30am on Tuesday, 31 March 2015 at Instinctif
Partners' offices at 65 Gresham Street, London EC2V 7NQ.
Analysts who wish to participate should contact Instinctif Partners on +44 (0)20 7457 2020 or email e-therapeutics@instinctif.comto register.
-Ends-

Contacts: e-Therapeutics plc

Steve Medlicott
Tel: +44 (0) 1993 883125 www.etherapeutics.co.uk

N+1 Singer LLP

Aubrey Powell / Jen Boorer Tel: +44 (0)20 7496 3000 www.n1singer.com

Instinctif Partners

Melanie Toyne-Sewell / Emma Barlow
Tel: +44 (0) 20 7457 2020
Email: e-therapeutics@instinctif.com

About e-Therapeutics plc

e-Therapeutics is an AIM-quoted drug discovery and development company with a proprie- tary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company's discovery and devel- opment activity is currently focused in cancer and disorders of the nervous system.
e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company, please visit www.etherapeutics.co.uk.

distributed by